Sym-Bio, entrepreneurial Chinese diagnostic company with a production line of infectious disease testing, has agreed to be acquired by PerkinElmer, international corporations with businesses newborn testing services in the life sciences and the environment. Sym-Bio wants to accelerate its growth and competitiveness in China through this strategic move, and PerkinElmer is seeking to expand its access to the Chinese market, using price advantages, working in China, and then the talent pool of young Chinese scientists. Strategic and operational integration of Sym-Bio in PerkinElmer studied through the prism of the founder and CEO of Sym-Bio and the acquiring company.
To enhance their effectiveness, color cases should be printed in color. "Hide
by Vicki L. Sato, Christoph Jaeker, Karim Reda Source: HBS 17 pages. Publication Date: November 13, 2011. Prod. #: 612032-PDF-ENG
Related Case Solutions & Analyses:
Childrens Hospital and Clinics (A)
Leadership for New Managers Business Fundamentals Series (2nd Edition)
Shelley Capital and the Hedge Fund Secondary Market
Paul Capital and Project U: Secondary Sales of Private Equity Stakes Spreadsheet
Making Balanced Scorecard Work: The Worldclass Lighting Experience
Social Enterprise Spectrum: Philanthropy to Commerce
Diversity At Jpmorgan Chase: Right Is Good Enough For Me (A)
Totalline Transport
Supply chain Management and Distribution network Strategy
Apple Inc.
